Humira(CF) pen 40 MG/0.4 MLS
Ended Awarded Last action
- Contract number
- SPE2DR26F9CCM
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,265
Award facts
- Contract value 100% obligated
- $12,265.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $12,265.28 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL units. This competitive award, issued on December 29, 2025, with an ultimate completion date of December 30, 2025, represents a firm fixed-price transaction with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, has demonstrated substantial capability in fulfilling Defense Logistics Agency requirements through multiple competitively awarded contracts. The company's extensive portfolio includes a wide range of brand-name and generic medications, vaccines, and specialized medical supplies supporting military and veteran healthcare systems globally. HUMIRA, a leading biologic immunosuppressant used primarily for rheumatoid arthritis and other autoimmune conditions, reflects the specialized pharmaceutical products the company routinely supplies to support military healthcare programs. As a child contract under the DLA's comprehensive pharmaceutical prime vendor framework, this award showcases AmerisourceBergen's role in ensuring consistent access to critical medications across the Defense Health Agency and other federal healthcare systems.
Quick answers
Who was awarded contract SPE2DR26F9CCM?
SPE2DR26F9CCM was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 29, 2025.
How much is contract SPE2DR26F9CCM worth?
The government has obligated $12,265 on SPE2DR26F9CCM.
Is contract SPE2DR26F9CCM an order under another contract?
Yes. SPE2DR26F9CCM is a delivery order under SPE2DR25D1017, an indefinite delivery contract.
Was contract SPE2DR26F9CCM competed?
The extent of competition for SPE2DR26F9CCM was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award